Loading...

We've got a brand new version of Simply Wall St! Try it out

Indus Holdings

CNSX:INDS
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
INDS
CNSX
CA$34M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Indus Holdings, Inc. cultivates, extracts, manufactures, markets, distributes, and sells cannabis products in California. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • Indus Holdings has significant price volatility in the past 3 months.
INDS Share Price and Events
7 Day Returns
5.3%
CNSX:INDS
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-
CNSX:INDS
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
INDS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Indus Holdings (INDS) 5.3% -16.5% -33.2% - - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • No trading data on INDS.
  • No trading data on INDS.
Price Volatility
Industry
5yr Volatility vs Market

INDS Value

 Is Indus Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Indus Holdings. This is due to cash flow or dividend data being unavailable. The share price is CA$4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Indus Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Indus Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:INDS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.53
CNSX:INDS Share Price ** CNSX (2019-09-19) in CAD CA$4
CNSX:INDS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $3.02
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Indus Holdings.

CNSX:INDS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:INDS Share Price ÷ EPS (both in USD)

= 3.02 ÷ -0.53

-5.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Indus Holdings is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Indus Holdings is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Indus Holdings's expected growth come at a high price?
Raw Data
CNSX:INDS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Indus Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Indus Holdings's assets?
Raw Data
CNSX:INDS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $1.85
CNSX:INDS Share Price * CNSX (2019-09-19) in CAD CA$4
CNSX:INDS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $3.02
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:INDS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:INDS Share Price ÷ Book Value per Share (both in USD)

= 3.02 ÷ 1.85

1.63x

* Primary Listing of Indus Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Indus Holdings is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Indus Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Indus Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

INDS Future Performance

 How is Indus Holdings expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
143.4%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Indus Holdings expected to grow at an attractive rate?
  • Unable to compare Indus Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Indus Holdings's earnings growth to the Canada market average as no estimate data is available.
  • Indus Holdings's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:INDS Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:INDS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 143.4%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:INDS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:INDS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 235 2
2019-12-31 55 2
2019-09-20
CNSX:INDS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 28 -36 -17
2019-03-31 21 -20 -11
2018-12-31 17 -18 -7
2017-12-31 15 -7 -7
2016-12-31 5 -4 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Indus Holdings is high growth as no earnings estimate data is available.
  • Indus Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:INDS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Indus Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:INDS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
2019-09-20
CNSX:INDS Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.53
2019-03-31 -1.06
2018-12-31 -0.68
2017-12-31 -0.82
2016-12-31 -0.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Indus Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Indus Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Indus Holdings has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

INDS Past Performance

  How has Indus Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Indus Holdings's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Indus Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Indus Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Indus Holdings's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Indus Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Indus Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:INDS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 27.60 -17.17 16.78
2019-03-31 21.33 -11.44 13.05
2018-12-31 17.20 -7.28 11.29
2017-12-31 15.47 -7.22 7.74
2016-12-31 4.68 -3.44 4.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Indus Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Indus Holdings has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Indus Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Indus Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Indus Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

INDS Health

 How is Indus Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Indus Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Indus Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Indus Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Indus Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 95x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Indus Holdings Company Filings, last reported 2 months ago.

CNSX:INDS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 59.81 0.57 14.81
2019-03-31 28.48 0.70 2.73
2018-12-31 34.13 0.40 10.31
2017-12-31 -5.15 12.28 2.23
2016-12-31 1.33 3.71 2.81
  • Indus Holdings's level of debt (1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Indus Holdings's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Indus Holdings has less than a year of cash runway based on current free cash flow.
  • Indus Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 65.2% each year.
X
Financial health checks
We assess Indus Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Indus Holdings has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

INDS Dividends

 What is Indus Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Indus Holdings dividends.
If you bought CA$2,000 of Indus Holdings shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Indus Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Indus Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:INDS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:INDS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2019-09-20

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Indus Holdings has not reported any payouts.
  • Unable to verify if Indus Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Indus Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Indus Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Indus Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Indus Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Indus Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

INDS Management

 What is the CEO of Indus Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Robert Weakley
TENURE AS CEO 5.7 years
CEO Bio

Mr. Robert Weakley is Co-Founder of Indus Holdings, Inc. and serves as Chief Executive Officer and Director. As Indus Holdings, Inc.’s leader, Mr. Weakley is responsible for overseeing the senior management team, as well as creating and implementing the strategic direction of Indus Holdings, Inc. and its award-winning brands. Having served as Chief Executive Officer since Indus Holdings, Inc.’s founding in 2014, Mr. Weakley has remained committed to Indus Holdings, Inc.’ overarching goals: creating products that emphasize consumer safety while advancing the changing perceptions of cannabis use. Having played a pioneering role in the emergence of the regulated cannabis market, Mr. Weakley has forged Partnerships with state and industry leaders to ensure positive growth in a highly regulated and evolving market. A 20-year veteran of the hospitality industry, Mr. Weakley evolved from hotel food and beverage operations into the large-scale epicurean event planning business in 2008 when he co-founded Coastal Luxury Management, a company widely recognized for producing annual luxury Food & Wine events in picturesque and influential destinations. As a budding restaurateur, Mr. Weakley was instrumental to the purchase of the historic Stokes Adobe building and opened Restaurant 1833 in the summer of 2011. In addition, Coastal Luxury Management launched Cannery Row Brewing Co. in Monterey, CA in the summer of 2010, featuring the largest selection of beer on tap in Northern California. In December 2013, the company Partnered with The Cosmopolitan of Las Vegas to open Rose. Rabbit. Lie., a venue blurring the lines between restaurant, entertainment space and nightclub. In early 2014, Coastal Luxury Management opened its first downtown Los Angeles restaurant, the acclaimed Faith & Flower. Previously, Mr. Weakley spent six years as the Executive Assistant Manager and Food and Beverage Director for the world-renowned Highlands Inn Park Hyatt in Carmel, California. He has also held management positions at Park Hyatt in Beaver Creek, Colorado; Prairie Restaurant in Chicago; and the Grand Hyatt in Tampa Bay, Florida. Mr. Weakley is a graduate of Paul Smith’s College in Paul Smiths, New York and holds a degree in Culinary Arts/Chef Training and Hospitality Management. He serves on the executive Board for Boys and Girls Club of Monterey County; the Workforce Investment Board for Monterey County as Chair of the planning committee, a 43-person Board comprised of community leaders; and the Monterey Business Council. Maintaining ties to the culinary industry, Mr. Weakley is also a Board Member of the Monterey County Wine Educational Foundation and is a regional Board Member for the international gastronomic society Chaine des Rotisseurs. A certified sommelier and a Member of Les Toques Blanc and the International Wine and Food Society, Mr. Weakley is a past national Board Member for the American Institute of Wine & Food.

CEO Compensation
  • Insufficient data for Robert to compare compensation growth.
  • Insufficient data for Robert to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Robert Weakley

TITLE
Co-Founder & CEO
TENURE
5.7 yrs

Joe Bayern

TITLE
President
AGE
56

Mark Ainsworth

TITLE
Executive VP

Tina Maloney

TITLE
Corporate Secretary
AGE
56
TENURE
1.7 yrs

Anand Menon

TITLE
Vice President of Operations

Kelly McMillan

TITLE
Chief Compliance Officer

Mark Russ

TITLE
Vice President of Sales

Alan Kropf

TITLE
Vice President of Marketing
Board of Directors Tenure

Average tenure and age of the Indus Holdings board of directors in years:

0.7
Average Tenure
68
Average Age
  • The average tenure for the Indus Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mark Ainsworth

TITLE
Executive VP

Tina Maloney

TITLE
Corporate Secretary
AGE
56
TENURE
1.7 yrs

Stephanie Harkness

TITLE
Director
AGE
75
TENURE
0.7 yrs

Sam Tramiel

TITLE
Director
AGE
68
TENURE
0.7 yrs

Bill Anton

TITLE
Director
AGE
78
TENURE
0.7 yrs

Arthur Maxwell

TITLE
Director
AGE
61
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Indus Holdings individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
04. Jul 19 Buy Stephanie Harkness Individual 08. Jun 19 08. Jun 19 8,345 CA$5.99 CA$49,995
04. Jul 19 Buy Sam Tramiel Individual 13. Jun 19 28. Jun 19 20,000 CA$5.65 CA$106,359
X
Management checks
We assess Indus Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Indus Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

INDS News

Simply Wall St News

Have Insiders Been Buying Indus Holdings, Inc. (CNSX:INDS) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Indus Holdings, Inc. … For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' View our latest analysis for Indus Holdings The Last 12 Months Of Insider Transactions At Indus Holdings In the last twelve months, the biggest single purchase by an insider was when Director Sam Tramiel bought CA$106k worth of shares at a price of CA$5.65 per share. … CNSX:INDS Recent Insider Trading, July 12th 2019 Indus Holdings Insiders Bought Stock Recently It's good to see that Indus Holdings insiders have made notable investments in the company's shares.

Simply Wall St -

INDS Company Info

Description

Indus Holdings, Inc. cultivates, extracts, manufactures, markets, distributes, and sells cannabis products in California. It offers its products under the House Weed, The Original Pot Co., MOON, Acme, Beboe, Dixie Elixirs & Edibles, and Orchid Essentials brand names. The company was founded in 2014 and is headquartered in Salinas, California.

Details
Name: Indus Holdings, Inc.
INDS
Exchange: CNSX
Founded: 2014
CA$34,015,132
8,503,783
Website: http://indusholdingsinc.com
Address: Indus Holdings, Inc.
19 Quail Run Circle,
Suite B,
Salinas,
California, 93907,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX INDS Subordinate Voting Shares Canadian National Stock Exchange CA CAD 30. Apr 2019
OTCPK INDX.F Subordinate Voting Shares Pink Sheets LLC US USD 30. Apr 2019
Number of employees
Current staff
Staff numbers
0
Indus Holdings employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:29
End of day share price update: 2019/09/19 00:00
Last estimates confirmation: 2019/09/18
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.